Scholar Rock Holding (SRRK) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 EPS of -$0.81, with revenue near zero as the company remains pre-commercial.
• Scholar Rock ended 2025 with approximately $368 million in cash, cash equivalents, and marketable securities, supporting operations into 2028.
• Focus on updates for apitegromab, with PDUFA target action date of September 22, 2026, for spinal muscular atrophy (SMA) treatment.
• Historical EPS beats, including Q4 2025's -$0.76 actual vs. -$0.86 expected, drove an 8% premarket stock surge.
• Key metrics to watch: R&D expenses, cash burn rate, and any regulatory or trial progress.
• Consensus remains bullish, with average price target around $56 amid pipeline optimism.

Earnings Context and Why It Matters

Scholar Rock (SRRK), a late-stage biopharmaceutical company developing treatments for neuromuscular diseases, approaches its Q1 2026 earnings on May 7, 2026. This report, covering the quarter ended March 31, 2026, is pivotal as investors gauge progress toward the September 2026 PDUFA date for apitegromab in spinal muscular atrophy (SMA). Recent quarters showed controlled cash burn and pipeline advancements, but biotech volatility hinges on clinical and regulatory news. With shares trading near $49 amid analyst buy ratings, this earnings could signal launch readiness or delays, influencing sentiment in a competitive neuromuscular space.

Earnings Expectations

Wall Street anticipates minimal revenue for Q1 2026, consistent with Scholar Rock's pre-commercial status, with consensus near $0. EPS consensus stands at -$0.81, reflecting ongoing R&D investments (research and development). Investors will scrutinize cash usage after Q4 2025's $91 million net loss, though the company's $368 million cash pile provides runway.

Historical trends show resilience: Scholar Rock has frequently beaten EPS estimates, as in Q4 2025 (-$0.76 vs. -$0.86 expected) and prior quarters. Stock reactions have been positive on beats, with an 8.46% premarket gain post-Q4. Guidance on burn rate and apitegromab milestones will be critical, alongside any SMA topline data or manufacturing updates.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment is cautiously optimistic, buoyed by Q4 beats and pipeline catalysts. Shares have climbed about 6% over the past month, trading around $49, near 52-week highs. Risks include higher-than-expected burn or regulatory delays, but historical post-earnings pops on beats suggest upside potential. Analysts maintain "Buy" ratings, with targets implying 15-20% gains.

Forward Outlook and Key Factors to Monitor

Post-earnings, attention will shift to apitegromab's PDUFA on September 22, 2026, a potential commercialization milestone for SMA patients. Success here could validate Scholar Rock's myostatin inhibition approach, differentiating it in neuromuscular therapeutics.

Investors should track cash burn trends; with $368 million on hand, the company guides runway into 2028, but commercialization ramps could accelerate spending. R&D expense trajectory, especially manufacturing and late-stage trials, will indicate launch preparedness.

Broader dynamics include SMA market growth and competition from gene therapies. Upcoming catalysts: topline data readouts, partnership announcements, or FDA feedback. Balanced monitoring of these will inform pipeline viability amid biotech sector volatility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations